$nktr nektarded update hotel room w a pool. 😘

NEW RESEARCH by former professors at Harvard and UC-Berkeley answers the question: How do tenant protections like "just cause eviction," right-to-counsel, and source-of-income impact rents? Answer: They drive up rents -- especially for the lowest-income renters. Findings: 🧵

$agen any thoughts on tomorrow's call? Inclusion of Dr. DeVito is interesting. This is his study: clinicaltrials.gov/study/NCT06268… Hearing from CCTG is appreciated by this investor on the p3. Zydus closing updates is interesting.

I remember seeing someone (maybe Ossium Research?) mention that $MIST’s Cardymist (etripamil) was being manufactured at the Catalent plant now owned by Novo. If that’s true, this latest FDA Form 483 on the site could explain a lot—possibly even tie into the recent CRL [change of

How is this possible? This cannot be right!

$17 $sndx

$atyr where is the p2 OLE data?

New slides from hcw showing dose response, and the nurr1 neuroprotective element regardless of active inflammation. Cdw seems to be flat on the extension phase. A lot lot of warrants at .75 strike has been holding this back. Fully diluted it's about a $350m cap. The big rms

why so much censoring?

I'm long flu & covid $ivvd & $cdtx

$atyr

RIP $REPL 2016 - 2025

$sndx - NCCN - 2A recommendation for mNP1 r/r AML - this is a pretty big label expansion. Company keeps executing.

$qure been beating the drum here a long time. Any treatment for HD not targeting EXON 1 is going to fail.

$imrx - someone talk me out of buying this before the open I cannot think of any reason - market cap under 500m - Sanofi just bought in - this is real competition for $rvmd mcap >8b ir.immuneering.com/news-releases/…

$qure spend a minute reading the comments. This is why I invest in biotech.